— Main Menu —
HOME
DCVAX ® TECHNOLOGY
- About DCVax®
- Dendritic Cell Immunotherapy
- Patient Stories & Physician Comments
PRODUCT CANDIDATES
- DCVax® – L
- DCVax® – Direct
- DCVax® – Prostate
CLINICAL TRIALS
- DCVax® – L Phase III for GBM Brain Cancer
- DCVax® – Direct Phase I/II for All Types of Inoperable Solid Tumor Cancers
INVESTORS & MEDIA
- Press Releases
- SEC Filings
- Webcasts
- Board Committee Charters
- Code of Conduct
- Notice of Proposed Settlement
- Related-Party Transaction Policy
- Corporate Governance Guidelines
ABOUT US
- Overview
- Company Management
- Publications
- Related Links
- Contact Us
- - General Inquiries
- - Patient Inquiries
HOME
DCVAX ® TECHNOLOGY
About DCVax®
Dendritic Cell Immunotherapy
Patient Stories & Physician Comments
PRODUCT CANDIDATES
DCVax® – L
DCVax® – Direct
DCVax® – Prostate
CLINICAL TRIALS
DCVax® – L Phase III for GBM Brain Cancer
DCVax® – Direct Phase I/II for All Types of Inoperable Solid Tumor Cancers
INVESTORS & MEDIA
Press Releases
SEC Filings
Webcasts
Board Committee Charters
Code of Conduct
Notice of Proposed Settlement
Related-Party Transaction Policy
Corporate Governance Guidelines
ABOUT US
Overview
Company Management
Publications
Related Links
Contact Us
General Inquiries
Patient Inquiries
Webcast: Dr. Marnix Bosch’s Presentation on DCVax® from ASCO 2018
